 BEIJING, May 19, 2021 GLOBE NEWSWIRE -- Burning Rock Biotech Limited NASDAQ: BNR, the Company or Burning Rock today announced the launch of the PRESCIENT Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT study, the first blood-based, pan-cancer early-detection study in China using a multi-omics approach. The study is going to be led by Professor Jie He, Fellow of the Chinese Academy of Sciences and head of the China National Cancer Center, and Professor Jie Wang. Both are residing physicians at the National Cancer Center and the Cancer Hospital of the Chinese Academy of Medical Sciences. 